759 related articles for article (PubMed ID: 21729796)
21. Off-label innovation: characterization through a case study of rhBMP-2 for spinal fusion.
Schnurman Z; Smith ML; Kondziolka D
J Neurosurg Spine; 2016 Sep; 25(3):406-14. PubMed ID: 27104282
[TBL] [Abstract][Full Text] [Related]
22. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2.
Vaidya R; Carp J; Sethi A; Bartol S; Craig J; Les CM
Eur Spine J; 2007 Aug; 16(8):1257-65. PubMed ID: 17387522
[TBL] [Abstract][Full Text] [Related]
23. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
[TBL] [Abstract][Full Text] [Related]
24. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
25. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study.
Comer GC; Smith MW; Hurwitz EL; Mitsunaga KA; Kessler R; Carragee EJ
Spine J; 2012 Oct; 12(10):881-90. PubMed ID: 23098617
[TBL] [Abstract][Full Text] [Related]
26. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
27. Revision surgery after interbody fusion with rhBMP-2: a cautionary tale for spine surgeons.
Rodgers SD; Marascalchi BJ; Grobelny BT; Smith ML; Samadani U
J Neurosurg Spine; 2013 Jun; 18(6):582-7. PubMed ID: 23560709
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
Roh JS; Yeung CA; Field JS; McClellan RT
J Orthop Surg Res; 2013 Dec; 8():49. PubMed ID: 24373225
[TBL] [Abstract][Full Text] [Related]
29. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
[TBL] [Abstract][Full Text] [Related]
30. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
31. Bone Morphogenetic Proteins in Anterior Cervical Fusion: A Systematic Review and Meta-Analysis.
Zadegan SA; Abedi A; Jazayeri SB; Nasiri Bonaki H; Jazayeri SB; Vaccaro AR; Rahimi-Movaghar V
World Neurosurg; 2017 Aug; 104():752-787. PubMed ID: 28315798
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
Dimar JR; Glassman SD; Burkus KJ; Carreon LY
Spine (Phila Pa 1976); 2006 Oct; 31(22):2534-9; discussion 2540. PubMed ID: 17047540
[TBL] [Abstract][Full Text] [Related]
33. Reply to "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned".
Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
Spine J; 2011 Nov; 11(11):1082-3; author reply 1083-6. PubMed ID: 22078853
[No Abstract] [Full Text] [Related]
34. Re: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Woo EJ
Spine J; 2011 Aug; 11(8):804; author reply 804-5. PubMed ID: 21925424
[No Abstract] [Full Text] [Related]
35. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
[TBL] [Abstract][Full Text] [Related]
36. Letter to the editor regarding "A critical review of recombinant human morphogenetic protein-2 trials in spine surgery: emerging safety concerns and lessons learned".
Anderson PA
Spine J; 2012 Apr; 12(4):356; author reply 356-7; discussion 357-9. PubMed ID: 22464143
[No Abstract] [Full Text] [Related]
37. A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2.
Pimenta L; Marchi L; Oliveira L; Coutinho E; Amaral R
J Neurol Surg A Cent Eur Neurosurg; 2013 Nov; 74(6):343-50. PubMed ID: 23444134
[TBL] [Abstract][Full Text] [Related]
38. Use of bone morphogenetic protein-2 for adult spinal deformity.
Luhmann SJ; Bridwell KH; Cheng I; Imamura T; Lenke LG; Schootman M
Spine (Phila Pa 1976); 2005 Sep; 30(17 Suppl):S110-7. PubMed ID: 16138058
[TBL] [Abstract][Full Text] [Related]
39. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes.
Slosar PJ; Josey R; Reynolds J
Spine J; 2007; 7(3):301-7. PubMed ID: 17482113
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database.
Woo EJ
Spine J; 2012 Oct; 12(10):894-9. PubMed ID: 23098616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
